KR102016077B1 - Food compositions for improving and preventing atopic dematitis skin condition - Google Patents
Food compositions for improving and preventing atopic dematitis skin condition Download PDFInfo
- Publication number
- KR102016077B1 KR102016077B1 KR1020180101667A KR20180101667A KR102016077B1 KR 102016077 B1 KR102016077 B1 KR 102016077B1 KR 1020180101667 A KR1020180101667 A KR 1020180101667A KR 20180101667 A KR20180101667 A KR 20180101667A KR 102016077 B1 KR102016077 B1 KR 102016077B1
- Authority
- KR
- South Korea
- Prior art keywords
- action
- weight
- parts
- skin
- food composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 235000013305 food Nutrition 0.000 title claims abstract description 28
- 206010003645 Atopy Diseases 0.000 title description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 24
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 13
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 12
- 244000246386 Mentha pulegium Species 0.000 claims abstract description 8
- 235000016257 Mentha pulegium Nutrition 0.000 claims abstract description 8
- 235000004357 Mentha x piperita Nutrition 0.000 claims abstract description 8
- 235000001050 hortel pimenta Nutrition 0.000 claims abstract description 8
- 240000001949 Taraxacum officinale Species 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 9
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 9
- 229910052737 gold Inorganic materials 0.000 claims description 9
- 239000010931 gold Substances 0.000 claims description 9
- 229910052709 silver Inorganic materials 0.000 claims description 9
- 239000004332 silver Substances 0.000 claims description 9
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- 235000019714 Triticale Nutrition 0.000 claims description 4
- 241000228158 x Triticosecale Species 0.000 claims description 4
- 241000218211 Maclura Species 0.000 abstract description 13
- 244000234609 Portulaca oleracea Species 0.000 abstract description 2
- 235000001855 Portulaca oleracea Nutrition 0.000 abstract description 2
- 241001106462 Ulmus Species 0.000 abstract description 2
- 244000167230 Lonicera japonica Species 0.000 abstract 2
- 235000017617 Lonicera japonica Nutrition 0.000 abstract 2
- 240000000011 Artemisia annua Species 0.000 abstract 1
- 235000001405 Artemisia annua Nutrition 0.000 abstract 1
- 240000000691 Houttuynia cordata Species 0.000 abstract 1
- 235000013719 Houttuynia cordata Nutrition 0.000 abstract 1
- 241001412277 Ixeridium dentatum Species 0.000 abstract 1
- 241001165529 Orostachys japonica Species 0.000 abstract 1
- 244000124853 Perilla frutescens Species 0.000 abstract 1
- 235000004348 Perilla frutescens Nutrition 0.000 abstract 1
- 241001499733 Plantago asiatica Species 0.000 abstract 1
- 244000202052 Poncirus trifoliata Species 0.000 abstract 1
- 235000000404 Poncirus trifoliata Nutrition 0.000 abstract 1
- 244000179560 Prunella vulgaris Species 0.000 abstract 1
- 235000010674 Prunella vulgaris Nutrition 0.000 abstract 1
- 241000534017 Saururus chinensis Species 0.000 abstract 1
- 241001251949 Xanthium sibiricum Species 0.000 abstract 1
- 244000085595 Zizania latifolia Species 0.000 abstract 1
- 235000004259 Zizania latifolia Nutrition 0.000 abstract 1
- 230000009471 action Effects 0.000 description 31
- 238000012360 testing method Methods 0.000 description 28
- 210000003491 skin Anatomy 0.000 description 18
- 230000000144 pharmacologic effect Effects 0.000 description 17
- 201000004624 Dermatitis Diseases 0.000 description 11
- 230000000844 anti-bacterial effect Effects 0.000 description 11
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 9
- 208000003251 Pruritus Diseases 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 208000010668 atopic eczema Diseases 0.000 description 8
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 7
- 108010082126 Alanine transaminase Proteins 0.000 description 7
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 7
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000006679 Mentha X verticillata Nutrition 0.000 description 6
- 235000002899 Mentha suaveolens Nutrition 0.000 description 6
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000001754 anti-pyretic effect Effects 0.000 description 6
- 229930003935 flavonoid Natural products 0.000 description 6
- 150000002215 flavonoids Chemical class 0.000 description 6
- 235000017173 flavonoids Nutrition 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 240000001851 Artemisia dracunculus Species 0.000 description 5
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 5
- 241000245665 Taraxacum Species 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 4
- 235000003097 Artemisia absinthium Nutrition 0.000 description 4
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 4
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 4
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 4
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 239000001138 artemisia absinthium Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000037380 skin damage Effects 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- 241000234282 Allium Species 0.000 description 3
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 3
- 240000002234 Allium sativum Species 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 3
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 3
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 240000003768 Solanum lycopersicum Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 3
- 240000000851 Vaccinium corymbosum Species 0.000 description 3
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 3
- 241000607598 Vibrio Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 239000011648 beta-carotene Substances 0.000 description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
- 235000013734 beta-carotene Nutrition 0.000 description 3
- 229960002747 betacarotene Drugs 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 235000021014 blueberries Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 235000004611 garlic Nutrition 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000020234 walnut Nutrition 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- 241000205585 Aquilegia canadensis Species 0.000 description 2
- 241001444063 Aronia Species 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000758791 Juglandaceae Species 0.000 description 2
- 241000238711 Pyroglyphidae Species 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 244000061458 Solanum melongena Species 0.000 description 2
- 235000002597 Solanum melongena Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 229960004784 allergens Drugs 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 229910052785 arsenic Inorganic materials 0.000 description 2
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 2
- 229910052793 cadmium Inorganic materials 0.000 description 2
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- DFBKLUNHFCTMDC-PICURKEMSA-N dieldrin Chemical compound C([C@H]1[C@H]2[C@@]3(Cl)C(Cl)=C([C@]([C@H]22)(Cl)C3(Cl)Cl)Cl)[C@H]2[C@@H]2[C@H]1O2 DFBKLUNHFCTMDC-PICURKEMSA-N 0.000 description 2
- 229950006824 dieldrin Drugs 0.000 description 2
- NGPMUTDCEIKKFM-UHFFFAOYSA-N dieldrin Natural products CC1=C(Cl)C2(Cl)C3C4CC(C5OC45)C3C1(Cl)C2(Cl)Cl NGPMUTDCEIKKFM-UHFFFAOYSA-N 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- DFBKLUNHFCTMDC-GKRDHZSOSA-N endrin Chemical compound C([C@@H]1[C@H]2[C@@]3(Cl)C(Cl)=C([C@]([C@H]22)(Cl)C3(Cl)Cl)Cl)[C@@H]2[C@H]2[C@@H]1O2 DFBKLUNHFCTMDC-GKRDHZSOSA-N 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 229940046533 house dust mites Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012435 Dermatitis and eczema Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000191070 Escherichia coli ATCC 8739 Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000020312 Thickened skin Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241001300088 Ulmus macrocarpa Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 208000016599 Uterine disease Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PQTCMBYFWMFIGM-UHFFFAOYSA-N gold silver Chemical compound [Ag].[Au] PQTCMBYFWMFIGM-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 231100001092 no hepatotoxicity Toxicity 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000013948 uterine smooth muscle contraction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Abstract
Description
본 발명은 아토피 피부염 예방 및 개선용 식품 조성물에 관한 것이다.The present invention relates to a food composition for preventing and improving atopic dermatitis.
아토피 피부염은 주로 유아기 또는 소아기에 시작되는 만성적이고 재발성의 염증성 피부질환으로, 소양증(가려움증)과 피부건조증, 특징적인 습진을 동반한다. 유아기에는 얼굴과 팔다리의 펼쳐진 쪽 부분에 습진으로 시작되지만, 성장하면서 특징적으로 팔이 굽혀지는 부분과 무릎 뒤의 굽혀지는 부위에 습진의 형태로 나타나게 되며, 많은 경우에 성장하면서 자연히 호전되는 경향을 보인다. 어른의 경우 접히는 부위 피부가 두꺼워지는 태선화가 나타나고, 유소아기에 비해 얼굴에 습진이 생기는 경우가 많다. 아토피 피부염은 세계적으로 증가하는 추세이며, 유병률이 인구의 20%라는 보고도 있다.Atopic dermatitis is a chronic, recurrent inflammatory skin disease that usually begins in infancy or childhood, accompanied by pruritus (itch), dry skin, and characteristic eczema. In infancy, it begins with eczema on the flanks of the face and limbs, but as it grows, it is characteristic of eczema on the bends of the arms and behind the knees, and in many cases it tends to improve naturally as it grows. . In adults, the skin becomes thicker in the folding area, and more eczema occurs on the face than in infants. Atopic dermatitis is on the rise worldwide, and the prevalence is reported to be 20% of the population.
이러한 아토피 피부염의 발병 원인은 아직 확실하게 알려져 있지 않은 상태이다. 임상 증상도 피부건조증, 습진 등으로 다양하게 나타나기 때문에 발병 원인이 어느 한 가지로만 설명될 수는 없지만, 환경적인 요인과 유전적인 소인, 면역학적 반응 및 피부보호막의 이상 등이 주요 원인으로 여겨지고 있다. 환경적인 요인으로는 산업화로 인한 매연 등 환경 공해, 식품첨가물 사용의 증가, 서구식 주거 형태로 인한 카펫, 침대, 소파의 사용 증가, 실내 온도 상승으로 인한 집 먼지 진드기 등의 알레르기를 일으키는 원인 물질(알레르겐)의 증가 등이 있다. 또한, 실내에서 애완동물을 키우는 일이 많아지면서 원인 물질에 노출되는 것도 원인이 된다. 한편, 아토피 피부염이 유전적인 영향을 받는 점은 많은 아토피 피부염 환자들이 가족력이 있다는 사실에서 알 수 있다.The cause of the development of atopic dermatitis is not yet known. Because clinical symptoms also appear in various cases such as dry skin and eczema, the cause of the disease cannot be explained by any one, but environmental factors, genetic predisposition, immunological reactions and abnormal skin barriers are considered to be the main causes. Environmental factors include allergens that cause allergies, such as environmental pollution, such as smoke from industrialization, increased use of food additives, increased use of carpets, beds, and sofas due to Western-style dwellings, and house dust mites due to increased room temperature. Allergens). In addition, as pets grow more indoors, exposure to causative agents is also a cause. On the other hand, the genetic effect of atopic dermatitis can be seen in the fact that many patients with atopic dermatitis have a family history.
아토피 피부염은 나이가 들면서 호전되거나 없어지는 경우가 많지만 호전된 후에도 특정 물질이나 자극에 의해 쉽게 가렵거나 염증 반응이 나타나는 경향이 있고, 성인기에 손 습진이 나타나는 경우가 많다. 성인기까지 아토피 피부염이 남는 경우에는 몸의 피부 증상은 호전되는 반면 얼굴에 홍반과 홍조 및 습진이 나타나는 경향이 있고, 접히는 부위는 오랫동안 긁어 피부가 두껍게 보이는 태선화 피부가 나타난다. 성인기라도 만성 습진만 나타나는 것이 아니라 만성 습진 위에 진물과 딱지가 앉는 급성 병변이 얼마 동안의 시간 간격을 두고 되풀이하여 일어난다. Atopic dermatitis often improves or disappears with age, but even when it improves, it tends to easily itch or inflammatory by specific substances or stimuli, and hand eczema often appears in adulthood. If atopic dermatitis remains until adulthood, the skin symptoms of the body improve, while erythema, redness, and eczema tend to appear on the face, and the folding area has a long rubbing skin, which shows the appearance of thickened skin. In adulthood, not only chronic eczema is present, but acute lesions with scabs and scabs on chronic eczema occur repeatedly over a period of time.
이러한 아토피성 피부염의 알려진 치료법으로는 세정(깨끗이 씻는 것)이 있다. 세정은 피부를 청결하게 유지하기 위해 샤워나 목욕 등을 하는 것으로, 피부에 묻은 먼지, 집먼지진드기, 피부 유해균, 땀, 기타 이물질 등을 씻어냄으로써, 아토피 피부의 악화요인을 제거하는 것이 중요하다. 특히, 땀을 많이 흘린 경우에는 잘 씻는 것이 필요하며, 적절한 세정을 하지 않거나, 과도한 세정을 할 경우에는 오히려 피부상태를 악화시킬 수 있다.Known treatments for such atopic dermatitis include washing. Cleaning is to take a shower or bath to keep the skin clean, and it is important to remove the deterioration factors of atopic skin by washing away dust, house dust mites, harmful bacteria, sweat, and other foreign substances on the skin. In particular, if you sweat a lot, it is necessary to wash well, and if not properly cleaned, or excessive cleaning may worsen the skin condition.
또한, 아토피성 피부염에 직접 도포하는 방법으로 연고를 바르는 방법이 있으나, 스테로이드에 대한 일반적인 부작용으로는 피부위축, 혈관확장, 탈색, 자반 등이 있고, 이에 피부를 약화시키고, 약화된 피부로 인해 모세혈관이 드러날 수 있다. 상기의 방법은 내성이 생겨 사용할수록 효과가 떨어질 수 있으며, 사용중단에 따른 반동현상(다시 재발됨)이 있을 수 있어서, 스테로이드 등의 연고를 바르는 방법은 증상이 심하지 않으면 가급적 사용을 자제하는 것이 좋다.In addition, there is a method of applying ointment by applying directly to atopic dermatitis, but common side effects for steroids include skin atrophy, vasodilation, discoloration, purpura, weakening the skin and capillary due to weakened skin Blood vessels may be exposed. The above method may be less effective as the resistance is used, and there may be a rebound phenomenon (recurrence) due to the discontinuation of use, so the method of applying ointments such as steroids should be avoided if possible without severe symptoms. .
또 하나의 방법으로는 내복약 복용이 있다. 이것은 스테로이드제제를 내복함으로써 그 효과를 바라는 것이다. 이것 역시 스테로이드 연고제와 마찬가지로 일시적인 효과는 기대할 수 있으나 지속적인 사용은 상기한 부작용을 발생시킬 수 있다.Another way is to take internal medicine. This is what the effect is hoped for by taking steroids. As with steroid ointments, this can also have a temporary effect, but continued use can cause the above side effects.
따라서, 본 발명의 목적은 금은화, 어성초, 자소엽, 인동초, 개똥쑥, 꾸지뽕잎, 꾸지뽕가지, 민들레, 하고초, 고장초, 마치현, 와송, 씀바귀, 유근피, 창이자, 차전초, 박하, 삼백초, 탱자를 이용하여 부작용 없이 아토피 피부염을 예방 및 개선할 수 있는 식품 조성물을 제공하는 것이다. Therefore, the object of the present invention is a gold silver flower, Eoseongcho, Jassop leaf, Indongcho, Firefly, Kudji mulberry leaf, Kudji branch, Dandelion, Hagocho, gwachocho, Machihyeon, Wasong, Seogwi, Yugeunpi, Changja, Chajeoncho, mint, triticale, tanza By using to provide a food composition that can prevent and improve atopic dermatitis without side effects.
본 발명의 다른 목적은 피부 가려움을 개선할 수 있는 식품 조성물을 제공하는 것이다. Another object of the present invention is to provide a food composition that can improve skin itching.
본 발명의 또 다른 목적은 우수한 항산화력을 갖는 식품 조성물을 제공하는 것이다. Another object of the present invention is to provide a food composition having excellent antioxidant power.
상기한 목적을 달성하기 위한 본 발명의 아토피 피부염 예방 및 개선용 식품 조성물은, 각각 100g씩의 금은화, 어성초, 자소엽, 인동초, 개똥쑥, 꾸지뽕잎, 꾸지뽕가지, 민들레, 하고초, 고장초, 마치현, 와송, 씀바귀, 유근피, 창이자, 차전초, 박하, 삼백초, 탱자의 건조물을 준비하여 100mesh로 분쇄하고, 이에 20중량배의 물을 가한 후, 80℃에서 10시간 동안 추출 및 여과한 추출물을 유효성분으로 함유하되, 상기 추출물은 물을 용매로 하여 추출되며, 상기 추출물은 금은화, 어성초, 자소엽, 인동초, 개똥쑥, 꾸지뽕잎, 꾸지뽕가지, 민들레, 하고초, 고장초, 마치현, 와송, 씀바귀, 유근피, 창이자, 차전초, 박하, 삼백초 및 탱자의 혼합물에 10~30중량배의 물을 가하고, 40~100℃에서 5~24시간 추출될 수 있다.
상기 추출물의 원료는, 금은화 100중량부, 어성초 10~200중량부, 자소엽 10~200중량부, 인동초 10~200중량부, 개똥쑥 10~200중량부, 꾸지뽕잎 10~200중량부, 꾸지뽕가지 10~200중량부, 민들레 10~200중량부, 하고초 10~200중량부, 고장초 10~200중량부, 마치현 10~200중량부, 와송 10~200중량부, 씀바귀 10~200중량부, 유근피 10~200중량부, 창이자 10~200중량부, 차전초 10~200중량부, 박하 10~200중량부, 삼백초 10~200중량부 및 탱자 10~200중량부일 수 있다.Food composition for preventing and improving atopic dermatitis of the present invention for achieving the above object, each of 100g gold and silver, eoseongcho, jasmine leaf, Indongcho, firewood, kkujippong leaves, kkujippongji, dandelion, haegocho, gyochocho, Machihyun, Wasong, nibbark, Yugeunpi, Changjaja, Chajeoncho, peppermint, three hundred seconds, tanza dried products were prepared and pulverized to 100mesh, 20 weight times of water was added, extracted and filtered for 10 hours at 80 ℃ effective It is contained as a component, the extract is extracted with water as a solvent, the extract is Geumhwa hwaseong, Eoseongcho, Jassop leaf, Indongcho, Ganoderma lucidum, Cudrania leaf, Cudrania branch, Dandelion, Hagocho, Korean gyocho, Machihyeon, Wasong, Seogwi , 10-30 weight times of water is added to the mixture of root skin, changja, chajeoncho, mint, 300 seconds and tanza, and can be extracted at 40-100 ° C. for 5 to 24 hours.
The raw material of the extract is 100 parts by weight of gold and silver, 10-200 parts by weight of eoseongcho, 10-200 parts by weight of Japonica leaves, 10-200 parts by weight of Indongcho, 10-200 parts by weight of firewood wormwood, 10-200 parts by weight of Cudrania leaf, Cudrania Eggplant 10-200 parts by weight, dandelion 10-200 parts by weight, hachocho 10-200 parts by weight, high-fat candle 10-200 parts by weight, guchi Prefecture 10-200 parts by weight, Wasong 10-200 parts by weight, moth 10-200 parts by weight It may be 10-200 parts by weight, root skin 10-200 parts by weight, Chang-ja 10-200 parts by weight, 10-200 parts by weight of mint, 10-200 parts by weight of mint, 10-200 parts by weight of 300 seconds, and 10-200 parts by weight of a tanza.
삭제delete
삭제delete
삭제delete
본 발명에 의하면, 식품 조성물의 섭취만으로 아토피성 피부염을 예방 및 개선할 수 있으며, 소양증(가려움증) 역시 개선할 수 있다는 장점이 있다. According to the present invention, it is possible to prevent and improve atopic dermatitis only by ingesting the food composition, and pruritus (itch) may also be improved.
도 1은 본 발명의 시험예 5에 따른 피부 손상 정도를 나타낸 그래프.
도 2는 본 발명의 시험예 5에 따른 혈청 IgE 발현양을 나타낸 그래프.
도 3은 본 발명의 시험예 5에 따른 혈청 histamine의 발현양을 나타낸 그래프.
도 4는 본 발명의 시험예 5에 따른 AST의 측정 결과를 나타낸 그래프.
도 5는 본 발명의 시험예 5에 따른 ALT의 측정 결과를 나타낸 그래프.
도 6은 본 발명의 시험예 5에 따른 Hematoxylin & eosin(H&E) 염색한 표피의 광학현미경 사진.
도 7은 본 발명의 시험예 5에 따른 표피의 두께 측정 결과를 나타낸 그래프.
도 8은 본 발명의 시험예 5에 따른 iNOS의 발현양을 나타낸 그래프.
도 9는 본 발명의 시험예 5에 따른 COX2의 발현양을 나타낸 그래프.1 is a graph showing the degree of skin damage according to Test Example 5 of the present invention.
Figure 2 is a graph showing the amount of serum IgE expression according to Test Example 5 of the present invention.
Figure 3 is a graph showing the amount of serum histamine expression according to Test Example 5 of the present invention.
Figure 4 is a graph showing the measurement results of the AST according to Test Example 5 of the present invention.
5 is a graph showing the measurement results of the ALT according to Test Example 5 of the present invention.
6 is an optical micrograph of the epidermis stained with Hematoxylin & eosin (H & E) according to Test Example 5 of the present invention.
7 is a graph showing the thickness measurement results of the epidermis according to Test Example 5 of the present invention.
8 is a graph showing the expression level of iNOS according to Test Example 5 of the present invention.
9 is a graph showing the expression amount of COX2 according to Test Example 5 of the present invention.
이하, 본 발명을 상세히 설명한다. Hereinafter, the present invention will be described in detail.
본 발명에 의한 아토피 피부염 예방 및 개선용 식품 조성물은, 금은화, 어성초, 자소엽, 인동초, 개똥쑥, 꾸지뽕잎, 꾸지뽕가지, 민들레, 하고초, 고장초, 마치현, 와송, 씀바귀, 유근피, 창이자, 차전초, 박하, 삼백초 및 탱자의 추출물을 유효성분으로 함유하는 것을 특징으로 한다. 즉, 이러한 추출물은 우수한 항산화 활성을 가지며, 이러한 항산화 활성에 의해 활성산소의 제거율이 매우 높음에 따라, 아토피 피부염을 예방 및 개선할 수 있는 것이다.Food composition for preventing and improving atopic dermatitis according to the present invention, gold and silver, eoseongcho, Jassop leaf, Indongcho, firewood, Cudrania leaf, Cudrania branch, Dandelion, Hachocho, Jijichocho, machihyeon, wasong, bittersweet, Yugeunpi, Changza, It is characterized by containing the extract of chajeoncho, peppermint, 300 seconds and tanza as an active ingredient. That is, such extracts have excellent antioxidant activity, and by this antioxidant activity, the removal rate of free radicals is very high, thereby preventing and improving atopic dermatitis.
여기서, 식품 조성물이란 음료, 차는 물론, 분말, 과립, 환, 정제, 캡슐, 캔디, 시럽 중에서 선택된 어느 하나의 제형을 포함하지만, 이에 한정하는 것은 아니다. Here, the food composition includes, but is not limited to, a beverage, a tea, as well as any one of powders, granules, pills, tablets, capsules, candy, and syrups.
그리고 상기 식품 조성물은 상기 추출물을 유효성분으로서 1~100중량%의 양으로 포함할 수 있다. And the food composition may include the extract in an amount of 1 to 100% by weight as an active ingredient.
또한, 본 발명의 식품 조성물은 공지의 첨가물을 더 포함할 수 있다. 이들 공지의 첨가물에는 구연산, 당류, 정백당 등을 비롯하여 공지의 식품에 첨가되는 각종 첨가물이 포함된다. 아울러, 본 발명 식품 조성물은 그 섭취량을 제한하지 않는다.In addition, the food composition of the present invention may further contain a known additive. These known additives include various additives added to known foods, including citric acid, sugars, white sugar and the like. In addition, the food composition of the present invention does not limit the intake amount.
예시적으로, 본 발명의 조성물을 건강 음료로 사용할 경우, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 텍스트린, 사이클로텐스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다.For example, when the composition of the present invention is used as a health beverage, various flavors or natural carbohydrates and the like may be contained as additional ingredients, as in the general beverage. The above-mentioned natural carbohydrates are sugars such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as textine and cyclotenstrin, xylitol, sorbitol and erythritol. As the sweetening agent, natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used.
그리고 추출원료인 금은화, 어성초, 자소엽, 인동초, 개똥쑥, 꾸지뽕잎, 꾸지뽕가지, 민들레, 하고초, 고장초, 마치현, 와송, 씀바귀, 유근피, 창이자, 차전초, 박하, 삼백초 및 탱자는 생초의 상태일 수도 있으며, 건조된 형태일 수 있는바, 이를 제한하지 않는다. Extracted raw materials such as gold, silver, Eoseongcho, Jassop leaf, Indongcho, Gadfly, Kudji leaf, Cudang branch, dandelion, haegocho, gwachocho, machihyeon, wasong, casserole, yugeunpi, changja, chajeoncho, peppermint, triticale and tanza It may be in a state, and may be in a dried form, but is not limited thereto.
본 발명에서 상기 추출물은 물을 용매로 하여 추출된 것으로, 상기 금은화, 어성초, 자소엽, 인동초, 개똥쑥, 꾸지뽕잎, 꾸지뽕가지, 민들레, 하고초, 고장초, 마치현, 와송, 씀바귀, 유근피, 창이자, 차전초, 박하, 삼백초 및 탱자의 혼합물에 10~30중량배의 물을 가하고, 40~100℃에서 5~24시간 추출 및 여과하여서 되는 것이다. 이러한 추출방법은 이 기술이 속하는 분야에서 충분히 공지된 것이므로, 이에 대한 상세한 설명은 생략한다. 아울러, 필요에 따라 농축 및 건조할 수 있음은 당연하다. In the present invention, the extract is extracted with water as a solvent, the gold and silver coins, Eoseongcho, Jassop leaf, Indongcho, Ganoderma lucidum leaf, Cudrania leaf, Cudrania branch, Dandelion, Hachocho, Jijacho, Machihyeon, Wasong, Seogwi, Yugeunpi, Changja, 10 to 30 times by weight of water is added to the mixture of chajeoncho, peppermint, 300 seconds and tanza, extracted and filtered for 5 to 24 hours at 40 ~ 100 ℃. Since such extraction method is well known in the art to which this technique belongs, a detailed description thereof will be omitted. In addition, it is natural that it can be concentrated and dried as needed.
이때, 상기 추출원료는 금은화 100중량부, 어성초 10~200중량부, 자소엽 10~200중량부, 인동초 10~200중량부, 개똥쑥 10~200중량부, 꾸지뽕잎 10~200중량부, 꾸지뽕가지 10~200중량부, 민들레 10~200중량부, 하고초 10~200중량부, 고장초 10~200중량부, 마치현 10~200중량부, 와송 10~200중량부, 씀바귀 10~200중량부, 유근피 10~200중량부, 창이자 10~200중량부, 차전초 10~200중량부, 박하 10~200중량부, 삼백초 10~200중량부 및 탱자 10~200중량부임이 바람직하나, 이를 반드시 제한하는 것은 아니다.At this time, the extract raw material is 100 parts by weight of gold and silver, 10-200 parts by weight of eoseongcho, 10-200 parts by weight of Jassop leaf, 10-200 parts by weight of Indongcho, 10-200 parts by weight of wormwood leaves, 10-200 parts by weight of Cudrania leaf, Cudrania Eggplant 10-200 parts by weight, dandelion 10-200 parts by weight, hachocho 10-200 parts by weight, high-fat candle 10-200 parts by weight, guchi Prefecture 10-200 parts by weight, Wasong 10-200 parts by weight, moth 10-200 parts by weight , 10 ~ 200 parts by weight,
상기와 같은 추출원료를 혼합하고, 이에 물을 가하여 추출한 추출물을 포함하는 식품 조성물은, 아토피성 피부염을 예방 및 개선하는 것은 물론, 가려움증 역시 개선할 수 있다는 장점이 있다.A food composition comprising an extract as described above and extracts by adding water to it, has the advantage of preventing and improving atopic dermatitis, as well as itching.
이하, 각 추출원료에 대하여 간략히 살펴보면 다음과 같다. Hereinafter, briefly look at each of the extraction raw materials as follows.
상기 금은화는 인동과의 인동덩굴 또는 그 변종의 꽃봉오리를 의미하는 것으로, 그 약리작용으로는 항균 작용, 항염증 작용, 해열 작용, 백혈구 탐식 작용 증가, 중추신경 흥분 작용, 혈청 콜레스테롤 강하 작용, 궤양 예방 등이 있다.The gold and silver coin means a bud of a honeysuckle or a variant thereof, and its pharmacological action includes antibacterial action, anti-inflammatory action, antipyretic action, leukocyte phagocytosis, central nervous excitability, serum cholesterol lowering action, and ulcer. Prevention, etc.
상기 어성초는 삼백초과의 약모밀의 개화기의 지상부를 의미하는 것으로, 그 약리작용으로는 항균 작용, 면역증강 작용, 항염증 작용, 이뇨 작용, 진해 작용 등이 있다.The eoseongcho refers to the ground portion of the flowering period of the weak wheat of more than three hundred, and the pharmacological action includes antibacterial action, immune enhancing action, anti-inflammatory action, diuretic action, antitussive action and the like.
상기 자소엽은 통화식물목 꿀풀과의 한해살이풀인 차조기의 잎을 의미하는 것으로, 그 약리작용으로는 해열 작용, 건위 작용, 항균 작용, 방부 작용 등이 있다.The foliar means a leaf of perennial herb that is an annual herb with the calliphytic plant Lamiaceae, and the pharmacological action includes antipyretic action, healthy action, antibacterial action, antiseptic action and the like.
상기 인동초는 인동덩굴의 줄기와 가지를 의미하는 것으로, 그 약리작용으로는 항균 작용, 건위 작용 등이 있다.The indongcho means stems and branches of the honeysuckle, and the pharmacological action is an antibacterial action, a healthy action and the like.
상기 개똥쑥은 쑥속 식물인 개똥쑥의 지상부를 의미하는 것으로, 그 약리작용으로는 해열 작용, 항염 작용, 항말라리아 작용, 항혈흡충(抗血吸蟲) 작용, 면역조절 작용, 항종양 작용, 항균 작용, 항바이러스 작용 등이 있다.The wormwood refers to the ground part of the wormwood, wormwood plant, the pharmacological action is antipyretic action, anti-inflammatory action, antimalarial action, anti-blood worms (抗 血吸蟲) action, immunoregulatory action, anti-tumor action, antibacterial action, Antiviral action.
상기 꾸지뽕은 뽕나무과의 낙엽활엽 소교목으로, 그 잎과 가지를 이용한다. 상기 꾸지뽕의 잎은 관절염, 피부병, 습진 등에 효과가 있으며, 가지는 신경통, 간염, 자궁질환 등에 효과가 있다.The kkujippong is a deciduous broad-leafed arborescent of the Mulberry family, using its leaves and branches. The leaves of the kkujippong is effective for arthritis, skin diseases, eczema, etc., the branch is effective for neuralgia, hepatitis, uterine disease.
상기 민들레는 꽃피기 전의 식물체를 의미하는 것으로, 종창, 유방염, 인후염, 맹장염, 복막염, 급성간염, 황달에 효과가 있다.The dandelion refers to a plant before flowering, and is effective in swelling, mastitis, sore throat, appendicitis, peritonitis, acute hepatitis and jaundice.
상기 하고초는 하고초의 꽃대를 의미하는 것으로, 그 약리작용으로는 혈압강하 작용, 항바이러스 작용, 항염 작용, 진통 작용 및 혈당강하 작용 등이 있다.The edible flower refers to the flower stalk of the edible fruit, and its pharmacological action includes blood pressure lowering action, antiviral action, anti-inflammatory action, analgesic action and hypoglycemic action.
상기 고장초는 천초라고도 불리는바, 고장초의 뿌리를 의미한다. 상기 고장초의 약리작용으로는 지혈 작용, 항종양 작용, 항균 작용, 항바이러스 작용, 항산화 작용, 항노화 작용 등이 있다.The sakuracho is also called cheoncho, means the root of the sachocho. The pharmacological action of the hypertonia is hemostatic action, antitumor action, antibacterial action, antiviral action, antioxidant action, anti-aging action and the like.
상기 마치현은 쇠비름의 전초를 의미하는 것으로, 그 약리작용으로는 항균 작용, 자궁평활근 수축력 증강으로 인한 장관 연동 작용, 이뇨 작용 등이 있다.Machihyeon means the outpost of purslane, its pharmacological action is antimicrobial action, uterine smooth muscle contraction due to enhancement of contractile force, diuretic action and the like.
상기 와송은 바위솔의 전초를 의미하는 것으로, 그 약리작용으로는 해열 작용, 향균 작용 등이 있다.The wasong means the outpost of the rock brush, the pharmacological action, such as antipyretic action, antibacterial action.
상기 씀바귀는 씀바귀의 전초를 의미하는 것으로, 그 약리작용으로는 해열 작용, 건위 작용, 조혈 작용, 소종 작용 등의 약리효과가 있다. The moth means the outpost of the moth, and the pharmacological action is a pharmacological effect, such as antipyretic action, sanitary action, hematopoietic action, swelling action.
상기 유근피는 느릅나무과의 왕느릅나무(Ulmus macrocarpa Hance)의 코르크층을 벗긴 수피를 의미하는 것으로, 유백피라고도 한다. 상기 유근피는 항암 작용 등의 약리작용이 있다.The roots of the roots of the root of the root of the elm (Ulmus macrocarpa Hance) of the cork bark, also referred to as milky skin. The roots of the roots have pharmacological effects such as anticancer action.
상기 창이자는 국화과의 도꼬마리의 열매를 의미하는 것으로, 그 약리작용으로는 혈당 강하 작용, 백혈구 감소 방지 작용, 진해 작용, 심장억제 작용 등이 있다.The changja means the fruit of the Asteraceae of the Asteraceae, and its pharmacological action includes hypoglycemic action, leukocyte reduction prevention action, antitussive action, cardiac suppression action, and the like.
상기 차전초는 질경이의 전초를 의미하는 것으로, 그 약리작용으로는 거담(祛痰) 작용, 지해(止咳) 작용, 위액 분비 조절 작용, 항궤양 작용, 소염 작용, 항종양 작용, 항균 작용 등이 있다.The chajeoncho means the outpost of plantain, the pharmacological action is expectoration (작용) action, subterranean (액) action, gastric juice secretion control action, anti-ulcer action, anti-inflammatory action, anti-tumor action, antibacterial action, etc. .
상기 박하는 박하의 지상부를 의미하는 것으로, 그 약리작용으로는 해열 작용, 소염 작용, 건위 작용, 담즙분비 촉진 작용 및 위장 평활근 억제 작용, 호흡기도의 점액분비 증가 작용, 중추신경 흥분 작용, 자궁수축 작용 등이 있다.The peppermint means the ground part of the peppermint, and its pharmacological action includes antipyretic action, anti-inflammatory action, palliative action, bile secretion promoting action and gastrointestinal smooth muscle suppression action, increased mucus secretion of the respiratory tract, central nervous excitatory action, uterine contraction Action.
상기 삼백초는 삼백초의 잎과 줄기를 의미하는 것으로, 그 약리작용으로는 이뇨 작용, 혈당 강하 작용, 항염 작용, 항균 작용, 혈소판응집 억제 작용 등이 있다.The three hundred seconds refers to the leaves and stems of three hundred seconds, the pharmacological action is a diuretic action, hypoglycemic action, anti-inflammatory action, antibacterial action, platelet aggregation inhibitory action.
상기 탱자는 탱자나무의 열매를 의미하는 것으로, 그 약리작용으로는 해독 작용, 두드러기, 피부염과 습진 완화 작용, 항염 작용 등이 있다.The tanza refers to the fruit of the tanza, its pharmacological action includes detoxification, urticaria, dermatitis and eczema relief, anti-inflammatory action.
이하, 실시예를 통해 본 발명을 상세히 설명한다. Hereinafter, the present invention will be described in detail through examples.
(실시예 1)(Example 1)
금은화, 어성초, 자소엽, 인동초, 개똥쑥, 꾸지뽕잎, 꾸지뽕가지, 민들레, 하고초, 고장초, 마치현, 와송, 씀바귀, 유근피, 창이자, 차전초, 박하, 삼백초 및 탱자의 건조물을 각 100g씩을 준비하였다. 그리고 상기 건조물을 100mesh 정도로 분쇄하고, 이에 20중량배의 물을 가한 후, 80℃에서 10시간 동안 유효성분을 추출하였다. 그리고 이를 filter paper(Hyundai, No.10)로 여과하였다. 100g each of gold and silver, Eoseongcho, Jassop leaf, Indongcho, Gadfly, Kudji leaf, Cudrania branch, Dandelion, Hagocho, Ganjacho, Machihyeon, Wasong, Mugwort, Yugeunpi, Changiza, Chajeoncho, Mint, Triticale and tanza It was. The dried product was pulverized to about 100 mesh, 20 weight times of water was added thereto, and the active ingredient was extracted at 80 ° C. for 10 hours. And it was filtered with filter paper (Hyundai, No. 10).
(시험예 1) (Test Example 1)
상기 실시예 1에 의한 식품 조성물의 위해요소를 확인하기 위하여, 대구한의대학교 한방생명자원연구소에 중금속 및 잔류농약 검사를 의뢰하였다. 그리고 그 결과를 하기 표 1에 나타내었다. In order to confirm the hazards of the food composition according to Example 1, a request was made to inspect heavy metals and residual pesticides at the Daegu Haany University Oriental Medical Life Research Institute. And the results are shown in Table 1 below.
하기 표 1에서와 같이, 상기 실시예 1에 의한 식품 조성물은 납, 비소, 수은, 카드뮴, 디디티, 디엘드린, 비에이치씨, 알드린, 엔드린이 모두 불검출되었음을 확인하였다.As shown in Table 1, the food composition according to Example 1 was confirmed that all of lead, arsenic, mercury, cadmium, Diditi, dieldrin, BC, Aldrin, and endrin were not detected.
(시험예 2) (Test Example 2)
상기 실시예 1에 의한 식품 조성물의 품질확인을 위하여, 주식회사 디아이분석센터에 타르색소, 납, 세균수, 대장균군의 검사를 의뢰하였다. 그리고 그 결과를 하기 표 2에 나타내었다. In order to confirm the quality of the food composition according to Example 1, a request was made to inspection of tar pigment, lead, bacterial count, and E. coli group to the DAI analysis center. And the results are shown in Table 2 below.
하기 표 2에서와 같이, 상기 실시예 1에 의한 식품 조성물은 타르색소, 납, 세균수, 대장균군이 모두 불검출되었음을 확인하였다. As shown in Table 2, the food composition according to Example 1 was confirmed that all tar, lead, bacteria, coliform group was not detected.
(시험예 3)(Test Example 3)
상기 실시예 1에 의한 식품 조성물의 항균 활성을 확인하기 위하여, 한국표준시험연구원에 녹농균, 대장균, 장염비브리오균, 황색포도상구균에 대한 항균 활성 시험을 의뢰하였다. 이때, 그 시험방법은 KS K 0693:2011에 따랐으며, 그 결과는 하기 표 3에 나타내었다. In order to confirm the antimicrobial activity of the food composition according to Example 1, an antimicrobial activity test for Pseudomonas aeruginosa, Escherichia coli, enteritis vibrio bacillus, and Staphylococcus aureus was commissioned to the Korea Testing Institute. At this time, the test method was in accordance with KS K 0693: 2011, the results are shown in Table 3 below.
하기 표 3에서와 같이, 상기 실시예 1에 의한 식품 조성물은 녹농균, 대장균, 장염비브리오균, 황색포도상구균에 대한 항균 활성이 우수함을 확인할 수 있었다.As shown in Table 3, the food composition according to Example 1 was confirmed that the antimicrobial activity against Pseudomonas aeruginosa, E. coli, enteritis Vibrio, Staphylococcus aureus.
ATCC 27853pseudomonas aeruginosa
ATCC 27853
ATCC 8739Escherichia coli
ATCC 8739
ATCC 17802Vibrio parahaemolycius
ATCC 17802
ATCC 6538Staphylococcus aureus
ATCC 6538
(시험예 4)(Test Example 4)
상기 실시예 1에 의한 식품 조성물의 β-카로틴과 총플라보노이드의 함량을 수원여자대학교 식품분석연구센터에 의뢰하여 시험하였다. 그리고 그 결과를 하기 표 4에 나타내었다. The content of β-carotene and total flavonoids in the food composition according to Example 1 was tested by the Food Analysis Research Center of Suwon Women's University. And the results are shown in Table 4 below.
하기 표 4에서와 같이, 상기 실시예 1에 의한 식품 조성물은 β-카로틴과 총플라보노이드의 함량이 매우 많음을 확인할 수 있었다. 이는 약용버섯류 중 가장 플라보노이드의 함량이 높은 상황버섯(대조군)보다도 플라보노이드의 함량이 약 1.3배 이상 많은 것임을 확인할 수 있었다. As shown in Table 4, the food composition according to Example 1 was confirmed that the content of β-carotene and total flavonoids is very high. It was confirmed that the content of the flavonoids is about 1.3 times or more than the situation mushroom (control group) having the highest flavonoid content among the medicinal mushrooms.
(시험예 5) (Test Example 5)
상기 실시예 1에 의한 식품 조성물의 아토피성 피부염에 대한 개선 효과를 시험하였다.The improvement effect on the atopic dermatitis of the food composition according to Example 1 was tested.
시료sample
상기 실시예 1의 식품 조성물을 동결 건조기(Eyela, Japan)에서 동결 건조하였다. 수득율은 25g/100mL 이였으며, 회수한 분말은 -20℃에서 보관하며 실험에 사용할 때 정제수를 이용하여 적당한 농도로 희석하여 사용하였다.The food composition of Example 1 was lyophilized in a freeze dryer (Eyela, Japan). The yield was 25g / 100mL, and the recovered powder was stored at -20 ° C and diluted to a suitable concentration with purified water when used in the experiment.
실험 동물Experimental animals
4주령의 male Balb/c 마우스(Daehan biolink, Korea)를 구입하여 순화 후 실험에 사용하였다. 사육실의 온도는 22±2℃, 습도 50±5%로 유지하였으며, 광주기와 암주기는 12시간으로 하였다. 동물실험은 대구한의대학교 동물실험윤리위원회의 승인을 받아 진행하였다.Four-week-old male Balb / c mice (Daehan biolink, Korea) were purchased and used for experiments after purification. The temperature of the feeding room was maintained at 22 ± 2 ℃ and
아토피 피부염의 유도 및 시료 처리Induction and Sample Processing of Atopic Dermatitis
실험동물의 등 부분을 제모 후, 다음날부터 2,4-dinitrochlorobenzene(DNCB, Sigma,USA)를 10% acetone과 olive oil 혼합액(3:1 부피비)으로 희석하여 200uL씩 3일간 등 부위에 도포하였다. 1차 면역반응을 유발한지 2일 후, 0.5%로 희석한 DNCB를 격일로 도포하여 아토피 피부염을 유발하였다.After epilation of the back of the experimental animals, 2,4-dinitrochlorobenzene (DNCB, Sigma, USA) was diluted with 10% acetone and olive oil mixture (3: 1 volume ratio) from the next day and applied to the back for 3 days. Two days after the induction of the first immune response, DNCB diluted to 0.5% was applied every other day to induce atopic dermatitis.
2주 뒤 상기 시료를 1일 4회(10:00, 12:00, 14:00, 16:00) 0.01, 0.5, 1g/mL로 증류수에 희석하여 100uL씩 2주간 경구투여하였다. 아울러, 시료 투여 기간에도 계속해서 DNCB를 격일로 도포하여 자연치유를 억제하였다. Two weeks later, the sample was diluted four times a day (10:00, 12:00, 14:00, 16:00) in distilled water at 0.01, 0.5, 1 g / mL, and orally administered at 100 uL for 2 weeks. In addition, during the sample administration period, DNCB was continuously applied every other day to suppress natural healing.
Control군은 시료를 대신하여 정제수를 100uL씩 2주간 경구투여하였으며, 양성대조군으로는 terfenadine를 아토피 피부염 유발부위에 도포하였다. In the control group, 100 uL of purified water was orally administered for 2 weeks in place of the sample, and as a positive control group, terfenadine was applied to the atopic dermatitis-induced site.
시험 결과Test result
가. 피부 손상 정도 측정end. Skin damage measurement
임상적 육안 평가법을 이용하여 실험동물의 피부 손상 정도(Clinical skin severity score)를 측정하였다. DNCB 용액을 도포하면 실험동물은 홍반/색소침착, 부종, 삼출/진물, 찰상, 태선화, 각질/피부건조 등이 일어나는데, 이 항목을 없음(0), 경증(1), 중증(2), 고증(3)으로 나누어 채점하였다. 그 결과는 도 1과 같았다.The clinical skin severity score was measured using clinical visual evaluation. The application of DNCB solution causes experimental animals to develop erythema / pigmentation, edema, exudation / dust, abrasions, thyroiditis, and keratin / skin dryness.This item is absent (0), mild (1), severe (2), severe It divided into (3) and scored. The result was as shown in FIG.
상기 시료를 1일 4회 2주간 경구투여한 뒤, 실험동물의 피부 손상 정도를 측정한 결과, 도 1과 같이, DNCB 도포한 control군은 8.0±0.24로 용매인 정제수만을 도포한 normal군에 비해 유의하게 피부가 손상되었고, 실험군인 시료 투여군은 농도별로 6.4±0.37, 6.0±0.15, 4.5±0.34로 손상되었는바, 농도 의존적으로 감소되었다. 양성대조군은 5.5±0.27로 control군에 비해 유의하게 피부가 회복되었다.After oral administration of the sample four times a day for two weeks, the skin damage of the test animal was measured. As shown in FIG. 1, the control group coated with DNCB was 8.0 ± 0.24 compared to the normal group coated with only purified water as a solvent. The skin was significantly damaged and the experimental group, which was the experimental group, was 6.4 ± 0.37, 6.0 ± 0.15, and 4.5 ± 0.34. The positive control group was 5.5 ± 0.27, which was significantly recovered from the control group.
나. 혈청 IgE, histamine의 발현양 측정I. Measurement of Serum IgE and Histamine Expression
실험이 끝난 뒤 실험동물의 복부에서 혈액을 채취 후 3,000rpm에서 10분간 원심분리하여 얻은 혈청으로 IgE(BD biosciences, USA)와 histamine kit(Abnova,Taiwan)를 이용하여 혈청 IgE, histamine의 발현양을 측정하였다. 그 결과는 도 2 및 3과 같았다.After the experiment, blood was collected from the abdomen of the animal and centrifuged at 3,000 rpm for 10 minutes. IgE (BD biosciences, USA) and histamine kit (Abnova, Taiwan) were used to measure the amount of serum IgE and histamine. Measured. The results were as shown in FIGS. 2 and 3.
도 2에서와 같이, control군에서 IgE는 알러지 반응과 관련한 면역글로불린으로 아토피 유발로 인하여 증가한 면역반응으로 인하여 수치가 증가하였고, 실험군인 시료 투여군 및 양성대조군에서는 수치가 감소하여 아토피를 억제할 것으로 생각되었다. As shown in Figure 2, IgE in the control group is an immunoglobulin associated with the allergic reaction, the level was increased due to the increased immune response due to atopic induction, and in the experimental group, the sample administration group and the positive control group, the level is thought to inhibit atopy It became.
비만세포의 고친화성 수용체와 IgE 항체가 결합한 상태에서 다시 항원의 자극을 받을 경우 histamine을 분비하는데, 도 3에서와 같이 이 역시 control군에서 증가하고, 실험군인 시료 투여군 및 양성대조군에서 수치가 감소하여 소양감 완화에 도움을 줄 수 있음을 확인하였다.When the antigen is stimulated again when the high affinity receptor and the IgE antibody of the mast cells are combined, histamine is secreted. As shown in FIG. 3, this also increases in the control group and decreases in the experimental group, the sample administration group and the positive control group. It was confirmed that it may help to reduce pruritus.
다. Alanine aminotransferase(ALT) and aspartate aminotransferase(AST)의 측정All. Determination of Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
AST와 ALT는 간질환의 진단에 널리 사용되는 효소로서, 혈청 중 간독성으로 인해 간세포의 괴사와 간조직의 파괴가 진행됨에 따라 효소가 혈중으로 유리되어 혈장 내에서 활성이 증가함으로 이 효소의 활성은 간 손상의 지표로 이용된다. 분리한 혈청으로 AST(GOT), ALT(GPT) kit(Asan Pharm Co, Korea)를 이용하여 ALT와 AST를 측정하고, 그 결과를 도 4 및 도 5에 나타내었다. AST and ALT are widely used in the diagnosis of liver disease. As the hepatotoxicity in serum causes necrosis of liver cells and destruction of liver tissue, the enzyme is released into the blood and its activity in plasma increases. Used as an indicator of liver damage. ALT and AST were measured using AST (GOT) and ALT (GPT) kit (Asan Pharm Co, Korea) as isolated serum, and the results are shown in FIGS. 4 and 5.
도 4 및 도 5에서 확인할 수 있는 바와 같이, AST와 ALT 측정 결과 모든군에서 혈액 화학적 기준지표의 기준에 크게 벗어나지 않음을 알 수 있었는바, 시료에 따른 간 독성은 없는 것으로 판단할 수 있었다.As can be seen in Figures 4 and 5, the results of the AST and ALT measurement was found that not significantly deviated from the standard of blood chemical reference indicators in all groups, it was determined that there is no liver toxicity according to the sample.
라. Hematoxylin & eosin(H&E) 염색la. Hematoxylin & eosin (H & E) staining
실험을 위해 희생한 실험동물의 등 쪽 피부를 채취하여 10% formalin에 넣고 고정한 뒤, 파라핀으로 포매하여 block을 만들었다. 그리고 이에 염증을 일으키는 epidermis, dermis를 확인할 수 있는 H&E 염색을 하고, 광학현미경(×100, Leica, Germany)을 이용하여 이를 촬영하였다. 그리고 그 결과를 도 6 및 도 7에 나타내었다. The dorsal skin of the sacrificed animal for the experiment was taken, fixed in 10% formalin, and embedded in paraffin to make blocks. In addition, H & E staining was performed to identify epidermis and dermis causing inflammation, and it was photographed using an optical microscope (× 100, Leica, Germany). The results are shown in FIGS. 6 and 7.
도 6 및 도 7에서와 같이, 정상군인 normal군의 epidermis 두께가 18.6±2.58um인 것에 비해 DNCB로 아토피 유발된 control군의 epidermis 두께는 78.0±5.84um로 피부 상처 및 자극으로 인하여 피부가 과형성 확장된 것을 확인할 수 있었다. 또한, 실험군의 경우 시료의 농도에 따라 각각 53.4±6.16, 53.5±2.66, 50.7±6.62um로 control군에 비하여 얇아졌고, 양성대조군 역시 38.3±4.41um로 control군에 비하여 얇아졌다. 이를 통해 DNCB로 인한 피부 손상에 따른 확장이 처리 시료에 의해 손상이 감소되었다는 것을 확인할 수 있었다.6 and 7, the epidermis thickness of the control group induced by atopic dermatitis with DNCB was 78.0 ± 5.84um, compared to the normal group having an epidermis thickness of 18.6 ± 2.58um. It could be confirmed. In addition, the experimental group was thinner than the control group at 53.4 ± 6.16, 53.5 ± 2.66, and 50.7 ± 6.62um, respectively, and the positive control group was also thinner than the control group at 38.3 ± 4.41um, respectively. This confirmed that the expansion due to skin damage caused by DNCB was reduced by the treated sample.
마. iNOS와 COX2의 발현양 측정hemp. Determination of expression levels of iNOS and COX2
iNOS와 COX2는 염증반응과 관련하여 대표적인 단백질로 아토피에서 발현양이 증가한다는 것이 밝혀져 있다. 실험을 위해 희생한 실험동물의 등부분 피부조직을 ripabuffer(Thermo, USA)를 이용하여 균질화 한 뒤 60ug의 단백질을 10% SDS gel에 전기영동하고, 이를 PVDF membrane(Roche, switzerland)에 옮겼다.iNOS and COX2 are representative proteins related to the inflammatory response and have been shown to increase the expression level in atopy. The back skin of the sacrificed animal was homogenized using ripabuffer (Thermo, USA), and 60 ug of protein was electrophoresed on a 10% SDS gel, which was transferred to a PVDF membrane (Roche, Switzerland).
1차 항체를 4℃에서 반응시키고 TBST를 이용하여 3회 세척한 후, 2차 항체를상온에서 1시간 반응시켜 ECL(Thermo, USA)를 이용하여 LAS 4000 mini(GEHealthcare, USA)에서 밴드를 확인하였다. 그리고 그 결과를 도 8 및 도 9에 나타내었다.After the primary antibody was reacted at 4 ° C. and washed three times using TBST, the secondary antibody was reacted at room temperature for 1 hour to confirm the band at
도 8 및 도 9에서 확인할 수 있는 바와 같이, DNCB로 아토피 유발된 control군에서 iNOS와 COX2의 발현양이 증가하였고, 실험군에서 농도 의존적으로 억제됨이 확인되었다.As can be seen in Figures 8 and 9, the expression level of iNOS and COX2 was increased in the control group induced by atopic dermatitis with DNCB, it was confirmed that the concentration is inhibited in the experimental group.
바. 통계 분석bar. Statistical analysis
모든 데이터 분석은 GraphPad Prism ver503을 이용하여 평균(Mean)과 평균의 표준오차(SEM)로 표시하였으며, 실험군 간의 유의성을 one way ANOVA 검증에 따라 Newman-Keuls test로 p<0.05 수준에서 검증하였다.All data analyzes were expressed in Mean and Standard Error (SEM) using GraphPad Prism ver503, and the significance between experimental groups was verified at p <0.05 level by Newman-Keuls test according to one way ANOVA.
(시험예 6)(Test Example 6)
상기 실시예 1에 의한 식품 조성물의 항산화 활성을 확인하기 위하여, 대구한의대학교 한방생명자원연구센터에 DPPH METHOD에 의한 항균활성 테스트를 의뢰하였다. 테스트 시 대조군으로는 마늘, 브로콜리, 블루베리, 아로니아, 양파, 토마토, 호두를 이용하였으며, 비타민 C를 기준값(100%)으로 하여 그 결과값을 계산하고, 이를 하기 표 5에 나타내었다.In order to confirm the antioxidant activity of the food composition according to Example 1, the antibacterial activity test by DPPH METHOD was requested to the Daegu Haany University Oriental Medicine Life Research Center. As a control group, garlic, broccoli, blueberries, aronia, onions, tomatoes, and walnuts were used, and the results were calculated using vitamin C as a reference value (100%), and the results are shown in Table 5 below.
표 5에서와 같이, 상기 실시예 1에 의한 식품 조성물은, 마늘, 브로콜리, 블루베리, 아로니아, 양파, 토마토, 호두에 비하여 항산화 활성이 현저히 우수함을 확인할 수 있었다. 따라서, 활성산소의 제거율 역시 우수할 것임을 판단할 수 있었다.As shown in Table 5, the food composition according to Example 1, it was confirmed that the antioxidant activity is significantly superior to garlic, broccoli, blueberries, aronia, onions, tomatoes, walnuts. Therefore, it could be determined that the removal rate of the active oxygen would also be excellent.
이상과 같이 명세서에서 최적 실시예가 개시되었다. 여기서 특정한 용어들이 사용되었으나, 이는 단지 본 발명을 설명하기 위한 목적에서 사용된 것이지 의미 한정이나 특허청구범위에 기재된 본 발명의 범위를 제한하기 위하여 사용된 것은 아니다. 그러므로 본 기술 분야의 통상의 지식을 가진 자라면 이로부터 다양한 변형 및 균등한 타 실시 예가 가능하다는 점을 이해할 것이다. 따라서 본 발명의 진정한 기술적 보호 범위는 첨부된 특허청구범위의 기술적 사상에 의해 정해져야 할 것이다.As described above, optimal embodiments have been disclosed in the specification. Although specific terms have been used herein, they are used only for the purpose of describing the present invention and are not used to limit the scope of the present invention as defined in the meaning or claims. Therefore, those skilled in the art will understand that various modifications and equivalent other embodiments are possible. Therefore, the true technical protection scope of the present invention will be defined by the technical spirit of the appended claims.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180101667A KR102016077B1 (en) | 2018-08-29 | 2018-08-29 | Food compositions for improving and preventing atopic dematitis skin condition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180101667A KR102016077B1 (en) | 2018-08-29 | 2018-08-29 | Food compositions for improving and preventing atopic dematitis skin condition |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102016077B1 true KR102016077B1 (en) | 2019-08-29 |
Family
ID=67775766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180101667A KR102016077B1 (en) | 2018-08-29 | 2018-08-29 | Food compositions for improving and preventing atopic dematitis skin condition |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102016077B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210135678A (en) * | 2020-05-06 | 2021-11-16 | 다그로 주식회사 | Method for Manufacturing Spice Sauce for Chicken Rib |
KR20230071413A (en) * | 2021-11-16 | 2023-05-23 | 박숙우 | Cosmetic materials for improving atopy dermatitis, Manufacturing method thereof and Cosmetics containing the same |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070095588A (en) * | 2006-03-22 | 2007-10-01 | 유니크인터네셔널 주식회사 | Nature room composite and the manufacture method for atopiseong skin disease treatment |
KR20090115609A (en) * | 2008-05-02 | 2009-11-05 | (주)아모레퍼시픽 | Medicinal plants extract using processing of herbal medicine and composition of skin external application comprising the same |
KR101043509B1 (en) | 2011-01-25 | 2011-06-23 | 이상권 | Preparation method of anhydride lactobaccilus fermentation health function food with respiratory organ disease and atopic dermatitis therapy improvement effects |
KR20140054620A (en) * | 2012-10-29 | 2014-05-09 | 정다운 | Food additive containing natural grass |
KR101839064B1 (en) | 2016-04-28 | 2018-03-22 | (주)신한에코 | Food compositions for improving atopic dermatitis skin condition using an extract of Stichopus japonicas red |
-
2018
- 2018-08-29 KR KR1020180101667A patent/KR102016077B1/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070095588A (en) * | 2006-03-22 | 2007-10-01 | 유니크인터네셔널 주식회사 | Nature room composite and the manufacture method for atopiseong skin disease treatment |
KR20090115609A (en) * | 2008-05-02 | 2009-11-05 | (주)아모레퍼시픽 | Medicinal plants extract using processing of herbal medicine and composition of skin external application comprising the same |
KR101043509B1 (en) | 2011-01-25 | 2011-06-23 | 이상권 | Preparation method of anhydride lactobaccilus fermentation health function food with respiratory organ disease and atopic dermatitis therapy improvement effects |
KR20140054620A (en) * | 2012-10-29 | 2014-05-09 | 정다운 | Food additive containing natural grass |
KR101839064B1 (en) | 2016-04-28 | 2018-03-22 | (주)신한에코 | Food compositions for improving atopic dermatitis skin condition using an extract of Stichopus japonicas red |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210135678A (en) * | 2020-05-06 | 2021-11-16 | 다그로 주식회사 | Method for Manufacturing Spice Sauce for Chicken Rib |
KR102367580B1 (en) | 2020-05-06 | 2022-02-25 | 춘천닭갈비생산자 영농조합법인 | Method for Manufacturing Spice Sauce for Chicken Rib |
KR20230071413A (en) * | 2021-11-16 | 2023-05-23 | 박숙우 | Cosmetic materials for improving atopy dermatitis, Manufacturing method thereof and Cosmetics containing the same |
KR102637448B1 (en) | 2021-11-16 | 2024-02-15 | 박숙우 | Cosmetic materials for improving atopy dermatitis, Manufacturing method thereof and Cosmetics containing the same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Baliga et al. | Chemistry and medicinal properties of the Bakul (Mimusops elengi Linn): A review | |
KR20110125318A (en) | Antibiotic composition comprising plants extract mixture | |
KR100847439B1 (en) | Trachelospermi caulis extracts compositions for treating or preventing inflammatory diseases | |
KR102016077B1 (en) | Food compositions for improving and preventing atopic dematitis skin condition | |
KR101192629B1 (en) | Composition for preventing and treating atopic dermatitis from domestic plant | |
KR20160114811A (en) | a composition comprising an extract of at least two crude drug consisting of Morus alba L, Schisandra chinenesis B and Asaparagus cochinchinensis, as an active ingredient for preventing or treating inflammation, allergy or asthma disease | |
KR20200018879A (en) | Natural cosmetic formulation with excellent effect for skin-microbiome homeostasis and anti-inflammation | |
KR101934794B1 (en) | Composition for preventing, improving or treating atopic dermatitis comprising extract mixture of Diospyros lotus leaf and grape fruit stem as effective component | |
KR20170054882A (en) | A pharmaceutical composition comprising cirsium japonicum | |
KR101717698B1 (en) | Composition comprising extract of Quercus acuta for prevention and treatment of hyperuricemia and metabolic disorders associated with hyperuricemia | |
KR100986975B1 (en) | Pharmaceutical composition for the treatment of atopic dermatitis | |
KR101345653B1 (en) | Compositions Comprising Sophora Subprostrata Extracts for Inhibiting the Activity of Acetylcholinesterase | |
KR20110090615A (en) | Composition for preventing or treating atopic dermatitis | |
KR102273066B1 (en) | Composition for improving chronic obstructive pulmonary disease using an extract of Podocarpus macrophyllus | |
KR101594034B1 (en) | Composition Comprising Extracts of Artemisia rubripes, Tubocapsicum anomalum and Camellia japonica (leaves) Improving Skin Allergy, Inflammation and Geriatric Odor | |
KR100900197B1 (en) | Compositions of ointments controlling skin immune system containing specific herbal extract complex | |
KR101282356B1 (en) | Composition comprising Acanthopanacis Cortex butanol fraction for preventing or treating gastrointestinal disease | |
KR101131719B1 (en) | Pulsatilla koreana extracts compositions for treating or preventing inflammatory diseases | |
KR20080101848A (en) | Herb extracts and functional food using the same for obviating and curing hangover | |
KR20170003153A (en) | A composition for the prevention and treatment of respiratory organ disease comprising the fractions of Asparagus cochinchinensis as an active ingredien | |
KR100967832B1 (en) | Antibacterial composition comprising the extract of artemisia and the extract of nelumbo nucifera gaertner as an active ingredient | |
KR101658429B1 (en) | Composition for preventing or improving atopic dermatitis comprising supercritical fluid extract of persimmon peel as effective component | |
KR100915893B1 (en) | Herb Extracts and Functional Food using the same for Obviating and Curing Hangover | |
Saranya et al. | The antioxidant and H+ K+ ATPase inhibitory effect of Andrographis paniculata and andrographolide-in vitro and in vivo studies | |
KR100689237B1 (en) | A pharmaceutical and food composition comprising an extract of Lespedeza bicolor having anti-oxidative activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |